Top

Cancer Causes & Control

Published in:

01-10-2008 | Original Paper

History of benign breast disease and risk of breast cancer among women in China: a case–control study

Authors: Tsogzolmaa Dorjgochoo, Sandra L. Deming, Yu-Tang Gao, Wei Lu, Ying Zheng, Zhixian Ruan, Wei Zheng, Xiao Ou Shu

Published in: Cancer Causes & Control | Issue 8/2008

Abstract

Background

Data from the Shanghai Breast Cancer Study were analyzed to evaluate the relationship between benign breast disease (BBD) and breast cancer among Chinese women with a self-report of physician-diagnosed BBD.

Methods

Study participants consisted of 3,452 breast cancer cases and 3,474 population controls recruited by the Shanghai Breast Cancer Study. In-person interviews were conducted to collect information on demographics and suspected risk factors for breast cancer, including a detailed history of BBD. Unconditional logistic regression was used to derive adjusted odds ratios (OR_adj) and 95% confidence intervals (CI) for the association between self-reported BBD and breast cancer.

Results

Women with breast cancer were significantly more likely to have a self-reported history of BBD including lobular proliferation (OR_adj = 1.6; 95% CI 1.4–1.8), fibroadenoma (OR_adj = 1.9; 95% CI 1.6–2.3), and other BBD (OR_adj = 1.6; 95% CI 1.3–2.1). Breast cancer risk was lower for surgically treated fibroadenoma as compared to non-surgically treated and higher for other BBDs that were surgically treated versus non-surgically treated.

Conclusions

Our results suggest that personal history of BBD is associated with an increased risk of future breast cancer among women in China. Surgical intervention for fibroadenoma may reduce the risk.

Available only for authorised users

Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA (2005) Global trends in breast cancer incidence and mortality 1973–1997. Int J Epidemiol 34:405–412PubMedCrossRef

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMed

Gao YT, Shu XO, Dai Q et al (2000) Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai breast cancer study. Int J Cancer 87:295–300PubMedCrossRef

Marchant DJ (2002) Benign breast disease. Obstet Gynecol Clin North Am 29:1–20PubMedCrossRef

Santen RJ, Mansel R (2005) Benign breast disorders. N Engl J Med 353:275–285PubMedCrossRef

Hartmann LC, Sellers TA, Frost MH et al (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237PubMedCrossRef

Aiello EJ, Buist DS, White E, Seger D, Taplin SH (2004) Rate of breast cancer diagnoses among postmenopausal women with self-reported breast symptoms. J Am Board Fam Pract 17:408–415PubMed

Page DL, Jensen RA, Simpson JF, Dupont WD (2000) Historical and epidemiologic background of human premalignant breast disease. J Mammary Gland Biol Neoplasia 5:341–349PubMedCrossRef

Fitzgibbons PL, Henson DE, Hutter RV (1998) Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer committee of the college of American pathologists. Arch Pathol Lab Med 122:1053–1055PubMed

10.

Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N (2004) Lower-category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 96:616–620PubMedCrossRef

11.

Dupont WD, Parl FF, Hartmann WH et al (1993) Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71:1258–1265PubMedCrossRef

12.

Marshall LM, Hunter DJ, Connolly JL et al (1997) Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 6:297–301PubMed

13.

Hughes LE, Mansel RE, Webster DJ (1987) Aberrations of normal development and involution (ANDI): a new perspective on pathogenesis and nomenclature of benign breast disorders. Lancet 2:1316–1319PubMedCrossRef

14.

Cheng J, Qiu S, Raju U, Wolman SR, Worsham MJ (2007) Benign breast disease heterogeneity: association with histopathology, age, and ethnicity. Breast Cancer Res Treat [Epub ahead of print 2007 Oct 5]

15.

Bodian CA, Perzin KH, Lattes R, Hoffmann P (1993) Reproducibility and validity of pathologic classifications of benign breast disease and implications for clinical applications. Cancer 71:3908–3913PubMedCrossRef

16.

Cook MG, Rohan TE (1985) The patho-epidemiology of benign proliferative epithelial disorders of the female breast. J Pathol 146:1–15PubMedCrossRef

17.

Courtillot C, Plu-Bureau, Binart N et al (2005) Benign breast diseases. J Mammary Gland Biol Neoplasia 10:325–335PubMedCrossRef

18.

Geneva Foundation for Medical Education and Research (2008) WHO collaborating centre in education and research in human reproduction

19.

World Health Organization (1968) Histological Typing of Breast Tumors. WHO Geneva

20.

Worsham MJ, Raju U, Lu M, Kapke A, Cheng J, Wolman SR (2007) Multiplicity of benign breast lesions is a risk factor for progression to breast cancer. Clin Cancer Res 13:5474–5479PubMedCrossRef

21.

Anonymous (2004) Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363:157–163

22.

Hislop TG, Elwood JM (1981) Risk factors for benign breast disease: a 30-year cohort study. Can Med Assoc J 124:283–291PubMed

23.

Webb PM, Byrne C, Schnitt SJ et al (2002) Family history of breast cancer, age and benign breast disease. Int J Cancer 100:375–378PubMedCrossRef

24.

Wu C, Ray RM, Lin MG et al (2004) A case–control study of risk factors for fibrocystic breast conditions: Shanghai nutrition and breast disease study, China, 1995–2000. Am J Epidemiol 160:945–960PubMedCrossRef

25.

Charreau I, Plu-Bureau, Bachelot A, Contesso G, Guinebretiere JM, Le MG (1993) Oral contraceptive use and risk of benign breast disease in a French case–control study of young women. Eur J Cancer Prev 2:147–154PubMedCrossRef

26.

Lubin JH, Brinton LA, Blot WJ, Burns PE, Lees AW, Fraumeni JF Jr (1983) Interactions between benign breast disease and other risk factors for breast cancer. J Chronic Dis 36:525–531PubMedCrossRef

27.

Dupont WD, Page DL, Parl FF et al (1994) Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 331:10–15PubMedCrossRef

28.

El-Wakeel H, Umpleby HC (2003) Systematic review of fibroadenoma as a risk factor for breast cancer. Breast 12:302–307PubMedCrossRef

29.

LiVolsi VA, Stadel BV, Kelsey JL, Holford TR (1979) Fibroadenoma in oral contraceptive users: a histopathologic evaluation of epithelial atypia. Cancer 44:1778–1781PubMedCrossRef

30.

Shabtai M, Saavedra-Malinger P, Shabtai EL et al (2001) Fibroadenoma of the breast: analysis of associated pathological entities—a different risk marker in different age groups for concurrent breast cancer. Isr Med Assoc J 3:813–817PubMed

31.

Roberts MM, Jones V, Elton RA, Fortt RW, Williams S, Gravelle IH (1984) Risk of breast cancer in women with history of benign disease of the breast. Br Med J (Clin Res Ed) 288:275–278

32.

Yu H, Rohan TE, Cook MG, Howe GR, Miller AB (1992) Risk factors for fibroadenoma: a case–control study in Australia. Am J Epidemiol 135:247–258PubMed

33.

Gateley CA, Bundred NJ, West RR, Mansel RE (1992) A case–control study of factors associated with macroscopic breast cysts. Eur J Cancer 28:125–127PubMedCrossRef

34.

Mauvais-Jarvis P, Kuttenn F, Gompel A (1986) Antiestrogen action of progesterone in breast tissue. Breast Cancer Res Treat 8:179–188PubMedCrossRef

35.

London SJ, Connolly JL, Schnitt SJ, Colditz GA (1992) A prospective study of benign breast disease and the risk of breast cancer. JAMA 267:941–944PubMedCrossRef

36.

Dixon JM, McDonald C, Elton RA, Miller WR (1999) Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group. Lancet 353:1742–1745PubMedCrossRef

37.

Ory H, Cole P, MacMahon B, Hoover R (1976) Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 294:419–422PubMedCrossRef

38.

Clavel F, Benhamou E, Sitruk-Ware R, Mauvais-Jarvis P, Flamant R (1985) Breast cancer and oral contraceptives: a review. Contraception 32:553–569PubMedCrossRef

39.

Budai B, Szamel I, Sulyok Z et al (2000) Influence of hormonal status of patients with cystic disease on the composition of cyst fluid and breast cancer risk. Anticancer Res 20:3879–3886PubMed

40.

Goehring C, Morabia A (1997) Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev 19:310–327PubMed

41.

Pike MC, Spicer DV, Dahmoush L, Press MF (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15:17–35PubMed

42.

Marchant DJ (2002) Inflammation of the breast. Obstet Gynecol Clin North Am 29:89–102PubMedCrossRef

43.

Zagorianakou P, Zagorianakou N, Stefanou D, Makrydimas G, Agnantis NJ (2006) The enigmatic nature of apocrine breast lesions. Virchows Arch 448:525–531PubMedCrossRef

44.

Anderson BO, Braun S, Carlson RW et al (2003) Overview of breast health care guidelines for countries with limited resources. Breast J 9(Suppl 2):S42–S50PubMedCrossRef

45.

Gupta RK, McHutchison AG, Dowle CS, Simpson JS (1993) Fine-needle aspiration cytodiagnosis of breast masses in pregnant and lactating women and its impact on management. Diagn Cytopathol 9:156–159PubMedCrossRef

46.

Scott-Conner CE, Schorr SJ (1995) The diagnosis and management of breast problems during pregnancy and lactation. Am J Surg 170:401–405PubMedCrossRef

47.

Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR (2004) A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol 159:308–317PubMedCrossRef

48.

Clegg LX, Potosky AL, Harlan LC et al (2001) Comparison of self-reported initial treatment with medical records: results from the prostate cancer outcomes study. Am J Epidemiol 154:582–587PubMedCrossRef

49.

Haapanen N, Miilunpalo S, Pasanen M, Oja P, Vuori I (1997) Agreement between questionnaire data and medical records of chronic diseases in middle-aged and elderly Finnish men and women. Am J Epidemiol 145:762–769PubMed

50.

Iversen L, Hannaford PC, Godden DJ, Price D (2007) Do people self-reporting information about chronic respiratory disease have corroborative evidence in their general practice medical records? A study of intermethod reliability. Prim Care Respir J 16:162–168PubMedCrossRef

51.

Madlensky L, McLaughlin J, Goel V (2003) A comparison of self-reported colorectal cancer screening with medical records. Cancer Epidemiol Biomarkers Prev 12:656–659PubMed

52.

Maunsell E, Drolet M, Ouhoummane N, Robert J (2005) Breast cancer survivors accurately reported key treatment and prognostic characteristics. J Clin Epidemiol 58:364–369PubMedCrossRef

53.

Puleo E, Zapka JG, Goins KV et al (2005) Recommendations for care related to follow-up of abnormal cancer screening tests: accuracy of patient report. Eval Health Prof 28:310–327PubMedCrossRef

54.

Canfell K, Beral V, Green J, Cameron R, Baker K, Brown A (2006) The agreement between self-reported cervical smear abnormalities and screening programme records. J Med Screen 13:72–75PubMedCrossRef

55.

Naughton-Collins M, Barry MJ, Caubet JF et al (2004) Validity of primary care patient self-report of abnormal (but not cancer) prostate biopsy results. J Urol 172:2366–2368CrossRef

Title: History of benign breast disease and risk of breast cancer among women in China: a case–control study
Authors: Tsogzolmaa Dorjgochoo
Sandra L. Deming
Yu-Tang Gao
Wei Lu
Ying Zheng
Zhixian Ruan
Wei Zheng
Xiao Ou Shu
Publication date: 01-10-2008
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 8/2008
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-008-9145-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2008

Dietary factors and risk of t(14;18)-defined subgroups of non-Hodgkin lymphoma

Association of Helicobacter pylori infection and diet on the risk of gastric cancer: a case–control study in Hawaii

Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study

Systematic review of prostate cancer’s association with body size in childhood and young adulthood

Lymphoma survival patterns by WHO subtype in the United States, 1973–2003

Flavonoid intake and liver cancer: a case–control study in Greece

Keynote webinar | Spotlight on antibody–drug conjugates in cancer